RAPP
HealthcareRapport Therapeutics, Inc.
$27.52
$-0.59 (-2.10%)
Jan 5, 2026
Price History (1Y)
Analysis
Rapport Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $1.31 billion and approximately 69 employees. The company's financial performance indicates significant losses, with net income totaling -$97,700,000 and EBITDA at -$109,099,000 in the trailing twelve months (TTM). Additionally, free cash flow is negative, standing at -$49,008,376. However, Rapport Therapeutics has a substantial amount of cash on hand, valued at $513.03 million, with relatively low debt levels of $11.87 million. The company's valuation metrics reveal a forward P/E ratio of -8.00 and an EV/EBITDA ratio of -7.69. The price to book ratio is 2.56, indicating that the stock price may be higher than its intrinsic value. Meanwhile, gross margin, operating margin, and profit margin are all at 0.0%, suggesting significant operational challenges. Returns on equity (ROE) and assets (ROA) are also negative, standing at -23.4% and -15.9%, respectively, indicating a need for improvement in the company's profitability.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.31B
- P/E Ratio
- N/A
- 52-Week High
- $42.27
- 52-Week Low
- $6.43
- Avg Volume
- 398.87K
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 69